Answers are grounded in this paper and cite their sources.
The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances.
No takes yet. Share an insight, caveat, or question.
Almarsson et al. (2004) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: